A Messer

Summary

Affiliation: Wadsworth Center
Country: USA

Publications

  1. ncbi Mini-review: polybrominated diphenyl ether (PBDE) flame retardants as potential autism risk factors
    Anne Messer
    Wadsworth Center, NY State Department of Health, 120 New Scotland Ave, Albany, NY 12208, United States
    Physiol Behav 100:245-9. 2010
  2. ncbi Developing intrabodies for the therapeutic suppression of neurodegenerative pathology
    Anne Messer
    Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA
    Expert Opin Biol Ther 9:1189-97. 2009
  3. ncbi Control of transcription in the RORa-staggerer mutant mouse cerebellum: glutamate receptor delta2 mRNA
    A Messer
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, PO Box 22002, Albany, NY 12201 2002, USA
    Int J Dev Neurosci 18:663-8. 2000
  4. ncbi An early-onset congenic strain of the motor neuron degeneration (mnd) mouse
    A Messer
    Wadsworth Center, New York State Department of Health, Albany, New York 12201, USA
    Mol Genet Metab 66:393-7. 1999
  5. ncbi A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease
    Todd W Miller
    Division of Genetic Disorders Wadsworth Center, New York State Department of Health, and Department of Biomedical Sciences, University at Albany, NY 12208, USA
    Neurobiol Dis 19:47-56. 2005
  6. ncbi The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse
    Valerie J Bolivar
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, 120 New Scotland Avenue, P O Box 22002, Albany, NY 12201, USA
    Brain Res 937:74-82. 2002
  7. ncbi Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice
    K Manley
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, New York, USA
    Nat Genet 23:471-3. 1999
  8. ncbi Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice
    K Manley
    David Axelrod Institute, Wadsworth Center, New York State Department of Health, New Scotland Avenue, P O Box 22002, Albany, NY 12201 2002, USA
    Brain Res 835:74-9. 1999
  9. ncbi A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease
    Robert C Murphy
    Wadsworth Center/David Axelrod Institute, New York State Department of Health and Department of Biomedical Sciences, University at Albany, P.O. Box 22002, Albany, NY 12201-2002, USA
    Brain Res Mol Brain Res 121:141-5. 2004
  10. ncbi Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice
    Valerie J Bolivar
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, 120 New Scotland Avenue, PO Box 22002, Albany, NY 12201 2002, USA
    Brain Res 1005:29-35. 2004

Research Grants

  1. Intrabody Therapy of Parkinson's Disease
    Anne Messer; Fiscal Year: 2003
  2. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2010
  3. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2007
  4. Gene therapy vectors for pediatric brain disease
    Anne Messer; Fiscal Year: 2003
  5. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2009

Collaborators

  • Valerie Bolivar
  • Silvia Gines
  • Abigail Snyder-Keller
  • J Marsh
  • Marcy MacDonald
  • Leslie Thompson
  • Gillian Bates
  • Todd W Miller
  • Erik Kvam
  • Chun Zhou
  • Michael R Sierks
  • William J Wolfgang
  • K Manley
  • Sandra M Lynch
  • J A McLear
  • Dmitry Goryunov
  • James S Huston
  • Jack M Webster
  • David W Colby
  • Robert C Murphy
  • J C Porter
  • R C Murphy
  • Charles B Shoemaker
  • Brent L Nannenga
  • Zongjian Jia
  • Min S Wang
  • D Lebrecht
  • W J Wolfgang
  • Conrad L Leung
  • Adijat Adebola
  • Julius J Jefferson
  • Ronald K H Liem
  • Nicholas D Mazarakis
  • Vernon Martin Ingram
  • John P Cassady
  • Sharareh Emadi
  • Martin Duennwald
  • K Dane Wittrup
  • Helen Zazulak
  • Susan Lindquist
  • Yijia Chu
  • Thomas L Shirley
  • Xiaowei Kang
  • A Peterson
  • J Plummer
  • L Flaherty
  • T L Shirley
  • J Pugh

Detail Information

Publications28

  1. ncbi Mini-review: polybrominated diphenyl ether (PBDE) flame retardants as potential autism risk factors
    Anne Messer
    Wadsworth Center, NY State Department of Health, 120 New Scotland Ave, Albany, NY 12208, United States
    Physiol Behav 100:245-9. 2010
    ..Such testing may help to prioritize extensive human epidemiological studies, as well as offer protocols for evaluation of future compounds...
  2. ncbi Developing intrabodies for the therapeutic suppression of neurodegenerative pathology
    Anne Messer
    Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA
    Expert Opin Biol Ther 9:1189-97. 2009
    ....
  3. ncbi Control of transcription in the RORa-staggerer mutant mouse cerebellum: glutamate receptor delta2 mRNA
    A Messer
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, PO Box 22002, Albany, NY 12201 2002, USA
    Int J Dev Neurosci 18:663-8. 2000
    ..Therefore, the results also suggest that the multiple innervation and the level of the receptor message are coordinated, either directly or indirectly...
  4. ncbi An early-onset congenic strain of the motor neuron degeneration (mnd) mouse
    A Messer
    Wadsworth Center, New York State Department of Health, Albany, New York 12201, USA
    Mol Genet Metab 66:393-7. 1999
    ..5 months. The early onset appears to correlate with levels of abnormal accumulating material, and should prove useful in elucidating NCL neurodegenerative mechanisms...
  5. ncbi A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease
    Todd W Miller
    Division of Genetic Disorders Wadsworth Center, New York State Department of Health, and Department of Biomedical Sciences, University at Albany, NY 12208, USA
    Neurobiol Dis 19:47-56. 2005
    ..Intrabodies may be used as potential curative agents, and as drug discovery tools, for HD and other misfolded protein disorders...
  6. ncbi The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse
    Valerie J Bolivar
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, 120 New Scotland Avenue, P O Box 22002, Albany, NY 12201, USA
    Brain Res 937:74-82. 2002
    ..Our results provide a link from the mutation via pathology to a quantifiable multidimensional behavioral phenotype of this naturally occurring mouse model of NCL...
  7. ncbi Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice
    K Manley
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, New York, USA
    Nat Genet 23:471-3. 1999
    ..16) with Msh2-/- mice. Our results show that Msh2 is required for somatic instability of the CAG repeat...
  8. ncbi Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice
    K Manley
    David Axelrod Institute, Wadsworth Center, New York State Department of Health, New Scotland Avenue, P O Box 22002, Albany, NY 12201 2002, USA
    Brain Res 835:74-9. 1999
    ..This in vitro system can now be used to assay factors that affect instability...
  9. ncbi A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease
    Robert C Murphy
    Wadsworth Center/David Axelrod Institute, New York State Department of Health and Department of Biomedical Sciences, University at Albany, P.O. Box 22002, Albany, NY 12201-2002, USA
    Brain Res Mol Brain Res 121:141-5. 2004
    ..Co-transfected anti-HD single-chain Fv (sFv) intrabodies can reverse this HD-specific increase in malonate-induced morbidity...
  10. ncbi Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice
    Valerie J Bolivar
    Wadsworth Center, New York State Department of Health, David Axelrod Institute, 120 New Scotland Avenue, PO Box 22002, Albany, NY 12201 2002, USA
    Brain Res 1005:29-35. 2004
    ..These behavioral abnormalities also occur prior to weight loss in the transgenic mice. Since we were able to detect an abnormal phenotype at an early age in R6/1 mice, this assay may be a useful tool for evaluating therapeutic agents...
  11. ncbi Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice
    Valerie J Bolivar
    Wadsworth Center, David Axelrod Institute, New York State Department of Health, Albany, New York 12201 2002, USA
    Behav Neurosci 117:1233-42. 2003
    ..These studies provide behavioral protocols suitable for high-throughput screening of therapeutic agents...
  12. ncbi Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice
    Abigail Snyder-Keller
    Wadsworth Center, NY State Department of Health, Albany, NY 12208, USA
    J Neuropathol Exp Neurol 69:1078-85. 2010
    ....
  13. ncbi Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease
    J A McLear
    Division of Genetic Disorders, Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12208, USA
    FASEB J 22:2003-11. 2008
    ..We conclude that a combinational approach of intrabody with enhanced Hsp70 expression is beneficial in addressing multiple pathologies associated with HD and has potential application for other neurodegenerative disorders...
  14. ncbi The motor neuron degeneration (mnd) gene acts intrinsically in motor neurons and peripheral fibroblasts
    J C Porter
    Department of Pediatrics, Albany Medical College, New York 12208, USA
    Mol Cell Neurosci 9:185-93. 1997
    ....
  15. ncbi Intrabody applications in neurological disorders: progress and future prospects
    Todd W Miller
    Wadsworth Center, New York State Department of Health, and Department of Biomedical Sciences, University at Albany, Albany, NY 12201, USA
    Mol Ther 12:394-401. 2005
    ....
  16. ncbi Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies
    William J Wolfgang
    Wadsworth Center, New York State Department of Health, Albany, NY 12201, USA
    Proc Natl Acad Sci U S A 102:11563-8. 2005
    ..They may also serve as tools for drug discovery and validation of sites on mutant neuronal proteins that could be exploited for rational drug design...
  17. ncbi Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity
    Erik Kvam
    Wadsworth Center, New York State Department of Health, Albany, New York, United States of America
    PLoS ONE 4:e5727. 2009
    ....
  18. ncbi Accelerated and widespread neuronal loss occurs in motor neuron degeneration (mnd) mice expressing a neurofilament-disrupting transgene
    J Plummer
    Wadsworth Center for Labs and Research, New York State Department of Health, Albany, New York 12201, USA
    Mol Cell Neurosci 6:532-43. 1995
    ..It further indicates that cytoskeletal abnormalities similar to those observed in late-onset human neurodegenerative disorders can interact with other cellular defects and contribute to pathogenesis...
  19. ncbi Gene transfer methods for CNS organotypic cultures: a comparison of three nonviral methods
    R C Murphy
    Wadsworth Center, New York State Department of Health, Albany, New York 12201-2002, USA
    Mol Ther 3:113-21. 2001
    ....
  20. ncbi An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity
    Sandra M Lynch
    Division of Genetic Disorders, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA
    J Mol Biol 377:136-47. 2008
    ....
  21. ncbi Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm
    Erik Kvam
    New York State Department of Health, Wadsworth Center David Axelrod Institute, 120 New Scotland Ave, PO Box 22002, Albany, NY 12201 2002, USA
    Protein Eng Des Sel 23:489-98. 2010
    ..These findings suggest that simple sequence analysis and electrostatic manipulation may aid in predicting and engineering solubility-enhanced intrabodies from antibody libraries for intracellular use...
  22. ncbi The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases
    Anne Messer
    Wadsworth Center, New York State Department of Health, Albany, New York 12201-2002, USA
    BioDrugs 20:327-33. 2006
    ..Such neurodegenerative diseases are therefore poised for engineered antibody approaches, which can provide a pipeline of novel therapeutics and new drug discovery tools...
  23. ncbi A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein
    Chun Zhou
    Wadsworth Center, New York State Department of Health, Albany, NY 12201, USA
    Mol Ther 10:1023-31. 2004
    ....
  24. ncbi Genetic mapping of farnesyltransferase alpha(Fnta) to mouse chromosome 8
    J C Porter
    Department of Pediatrics, Albany Medical College, Albany, New York 12208, USA
    Mamm Genome 7:622-3. 1996
  25. ncbi Mutant mouse models of ALS
    A Messer
    Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany
    Neurobiol Aging 15:247-8. 1994
  26. ncbi DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype
    Todd W Miller
    Department of Biomedical Sciences, State University of New York at Albany, 12203, USA
    Mol Ther 7:572-9. 2003
    ..Immunoresponsive HDR6/2 mice showed increased insulin staining more closely resembling wild-type levels. These observations suggest that DNA vaccination against toxic intracellular proteins may be therapeutic...
  27. ncbi Molecular characterization of the genetic lesion in Dystonia musculorum (dt-Alb) mice
    Dmitry Goryunov
    Department of Pathology, Columbia University College of Physicians and Surgeons, P and S 15 421, New York, NY 10032, USA
    Brain Res 1140:179-87. 2007
    ..Our identification of the 5' junction of the dt-Alb insertion makes it possible to genotype dt-Alb animals by standard PCR...
  28. ncbi Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody
    David W Colby
    Department of Chemical Engineering and Division of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 101:17616-21. 2004
    ..The demonstrated importance of disulfide bond-independent binding for intrabody potency suggests a generally applicable approach to the development of effective intrabodies against other intracellular targets...

Research Grants10

  1. Intrabody Therapy of Parkinson's Disease
    Anne Messer; Fiscal Year: 2003
    ..Long-term goals include administering these antibody reagents via gene therapy vectors, or as stable, multi-functional proteins. ..
  2. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2010
    ..These approaches should also be generally applicable for other neurodegenerative diseases that result from abnormal protein folding and accumulation, including Alzheimer's, Parkinson's, and prion diseases. ..
  3. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2007
    ..These approaches should also be generally applicable for other neurodegenerative diseases that result from abnormal protein folding and accumulation, including Alzheimer's, Parkinson's, and prion diseases. ..
  4. Gene therapy vectors for pediatric brain disease
    Anne Messer; Fiscal Year: 2003
    ..Once this assay system is in place for one vector, it can also be used to test modifications of vector specificity and expression, as well as additional vectors such as AAV complexes. ..
  5. Intrabodies as novel neurological therapeutics
    Anne Messer; Fiscal Year: 2009
    ..These approaches should also be generally applicable for other neurodegenerative diseases that result from abnormal protein folding and accumulation, including Alzheimer's, Parkinson's, and prion diseases. ..